The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Thyroid Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Contact: Study coordinator (For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) · prpl@cc.nih.gov · 800-411-1222

Study leads

Joanna Klubo-Gwiezdzinska, M.D.
Principal Investigator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Melanoma · Medullary Thyroid Cancer · Sinonasal Undifferentiated Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Tucson, United States · Seattle, United States

Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

Differentiated Thyroid Cancer

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

Breast Cancer, NOS · CNS Primary Tumor, NOS · Cervical Cancer, NOS

Abroad (travel likely)Recruiting

Fairbanks, United States · Kingman, United States

Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer

Recurrent Thyroid Cancer

Abroad (travel likely)RecruitingPHASE1

Baltimore, United States